首页> 外文期刊>Tropical Journal of Pharmaceutical Research >Therapeutic effect of co-administered salvianolate and atorvastatin calcium on coronary heart disease patients with angina pectoris, and their blood lipid levels``
【24h】

Therapeutic effect of co-administered salvianolate and atorvastatin calcium on coronary heart disease patients with angina pectoris, and their blood lipid levels``

机译:丹参多酚酸盐和阿托伐他汀钙并用对冠心病心绞痛患者及其血脂水平的治疗作用``

获取原文
           

摘要

Purpose: To investigate the clinical effect of combination of salvianolate and atorvastatin on blood lipids of coronary heart disease patients with angina pectoris (CHD-AP). Method: Patients with CHD-AP (n = 104) from January 2016 to January 2017 were randomly assigned to two groups: control group treated with atorvastatin (10 mg/day), and study group was administered atorvastatin (10 mg/day, oral) plus salvianolate (200 mg/day in 5 % glucose, iv). Palpitation, chest distress, improvement in myocardial ischemia, myocardial function, and hemodynamics were determined and used to assess treatment effectiveness in the two groups. Differences in blood lipid profiles were also investigated. Results: Improvement in palpitation, chest distress, myocardial ischemia and myocardial function in the study group were significantly higher than in the control group (p 0.05). In the study group, total cholesterol (TC), low density lipoprotein cholesterol (LDL-C) and triacylglycerols (TGs) significantly decreased, relative to the control group (p 0.05). Conclusion: Treatment of CHD-AP patients with combination of salvianolate and atorvastatin significantly ameliorates coronary heart disease and angina pectoris, and also reduces their blood lipid levels.
机译:目的:探讨丹参多酚酸盐和阿托伐他汀联合治疗对冠心病心绞痛(CHD-AP)患者血脂的影响。方法:将2016年1月至2017年1月患有CHD-AP的患者(n = 104)随机分为两组:对照组接受阿托伐他汀(10毫克/天)治疗,研究组接受阿托伐他汀(10毫克/天,口服) )加上丹参多酚酸酯(200 mg /天,在5%葡萄糖中,iv)。确定了心,、胸痛,心肌缺血,心肌功能和血流动力学的改善,并用于评估两组的治疗效果。还研究了血脂谱的差异。结果:研究组心pa,胸痛,心肌缺血和心肌功能的改善显着高于对照组(p <0.05)。在研究组中,相对于对照组,总胆固醇(TC),低密度脂蛋白胆固醇(LDL-C)和三酰基甘油(TGs)显着降低(p <0.05)。结论:丹参多酚和阿托伐他汀联合治疗CHD-AP患者可明显改善冠心病和心绞痛,并降低其血脂水平。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号